Quick Answer
BioCorRx Inc. reported Cash and Equivalents of $592.1 thousand for fiscal year 2020.
BioCorRx Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2020 | $592.1K | -77.6% |
| 2019 | $2.65M | +845.7% |
| 2018 | $279.8K | +27.1% |
| 2015 | $220.1K | +314.3% |
| 2014 | $53.1K | -51.1% |
| 2013 | $108.6K | +1708.8% |
| 2012 | $6.0K | +262.2% |
| 2011 | $1.7K | -76.8% |
| 2010 | $7.1K | -74.5% |
| 2009 | $27.9K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| June 30, 2022 | $111.5K | -84.1% | -47.7% |
| March 31, 2022 | $213.2K | -88.8% | +148.3% |
| December 31, 2021 | $85.8K | -85.5% | -88.5% |
| September 30, 2021 | $745.5K | -20.4% | +6.0% |
| June 30, 2021 | $703.2K | -52.0% | -63.2% |
| March 31, 2021 | $1.91M | -3.1% | +222.6% |
| December 31, 2020 | $592.1K | -77.6% | -36.8% |
| September 30, 2020 | $936.2K | -73.9% | -36.1% |
- BioCorRx Inc. showed a decrease of -77.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2020 period, BioCorRx Inc.’s cash and equivalents has grown by 2020.6% (from $27.9 thousand to $592.1 thousand).
- The most recent figure is from BioCorRx Inc.’s fiscal year 2021 report (Form 10-K), filed with the SEC on March 31, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: